title: Anxiolytic drug discovery: what are the novel approaches and how can we improve them?
abstract: BACKGROUND
  Contemporary biological psychiatry uses experimental (animal) models to increase our understanding of affective disorder pathogenesis. Despite the well-recognized spectrum nature of affective disorders, modern anxiolytic drug discovery mainly targets specific pathways and molecular determinants within a single phenotypic domain. However, greater understanding of the integrative mechanisms and pathogenesis is essential in order to develop new effective therapies.
  
  
  METHODS
  In this review, the authors emphasize the importance of a 'domain interplay-oriented' approach to experimental affective research. They also highlight the need to expand the scope of anxiolytic drug targets to better understand the pathogenesis of anxiety-spectrum disorders.
  
  
  CONCLUSIONS
  There is the potential to markedly improve the utility of animal models for affective disorders. First, the authors suggest that one such way would be by analyzing the systems of several domains and their interplay to better understand disease pathogenesis. Further, it could also be improved by expanding the range of model species and by extending the spectrum of anxiolytic drug targets; this would help to focus on emerging and unconventional systems to better develop new therapies.
authors.affiliation: ZENEREI Institute , 309 Palmer Court, Slidell, LA 70458 , USA +1 240 328 2275 ; +1 240 328 2275 ; avkalueff@gmail.com.
authors.forename: Adam Michael
authors.initials: AM
authors.lastname: Stewart
authors.forename: Allan V
authors.initials: AV
authors.lastname: Kalueff
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000379:methods; D006801:Humans
chemical_list: D014151:Anti-Anxiety Agents